Studies have reported that lung cancer patients with POLE mutation showed a better response to immunotherapy, which may be related to the high tumor mutation burden caused by POLE mutations.[51] Another study reported that POLE mutations can serve as independent biomarkers for predicting the efficacy of immunotherapy across multiple cancer types, providing more precise guidance for the clinical application of immunotherapy.[52] Although POLE mutations are associated with favorable responses to immunotherapy, their specific application as therapeutic targets still face many challenges. This evidence concerns the gene POLE and lung cancer.